These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 6423125)

  • 21. Adverse drug reactions.
    Turner P
    Hum Toxicol; 1986 May; 5(3):161-2. PubMed ID: 3710492
    [No Abstract]   [Full Text] [Related]  

  • 22. Drug utilization data in benefit analysis of drugs.
    Liljestrand A
    Acta Med Scand Suppl; 1984; 683():135-9. PubMed ID: 6204508
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [How to report side-effects of drugs?].
    Guillaume JC
    Ann Dermatol Venereol; 1986; 113(4):375-6. PubMed ID: 3767239
    [No Abstract]   [Full Text] [Related]  

  • 24. [Critical study of methods of postmarketing drug surveillance].
    Gut JP; Auriche M; Spriet-Pourra C; Juillet Y
    Therapie; 1985; 40(5):313-9. PubMed ID: 3913048
    [No Abstract]   [Full Text] [Related]  

  • 25. Postmarketing studies of drug efficacy: when must they be randomized?
    Strom BL; Miettinen OS; Melmon KL
    Clin Pharmacol Ther; 1983 Jul; 34(1):1-7. PubMed ID: 6861430
    [No Abstract]   [Full Text] [Related]  

  • 26. The computerized on-line Medicaid pharmaceutical analysis and surveillance system: a new resource for postmarketing drug surveillance.
    Strom BL; Carson JL; Morse ML; LeRoy AA
    Clin Pharmacol Ther; 1985 Oct; 38(4):359-64. PubMed ID: 3899458
    [No Abstract]   [Full Text] [Related]  

  • 27. Adverse drug reaction reporting.
    Bosco LA
    Am J Gastroenterol; 1987 Apr; 82(4):356-7. PubMed ID: 3565343
    [No Abstract]   [Full Text] [Related]  

  • 28. [Drug surveillance. Which methods? For which adverse effects? Application to teratogen monitoring].
    Goujard J
    Therapie; 1985; 40(5):287-92. PubMed ID: 4095683
    [No Abstract]   [Full Text] [Related]  

  • 29. Postmarketing studies of drug efficacy.
    Strom BL; Melmon KL; Miettinen OS
    Arch Intern Med; 1985 Oct; 145(10):1791-4. PubMed ID: 3899034
    [No Abstract]   [Full Text] [Related]  

  • 30. Spontaneous adverse drug reaction reports.
    Spiers D
    J R Soc Med; 1991 Nov; 84(11):691-2. PubMed ID: 1744887
    [No Abstract]   [Full Text] [Related]  

  • 31. New drugs. Adverse reactions. I.
    Bateman DN; Chaplin S
    Br Med J (Clin Res Ed); 1988 Mar; 296(6624):761-4. PubMed ID: 3126965
    [No Abstract]   [Full Text] [Related]  

  • 32. Medicaid drug-event data: an emerging tool for evaluation of drug risk.
    Jones JK; Van de Carr SW; Rosa F; Morse L; LeRoy A
    Acta Med Scand Suppl; 1984; 683():127-34. PubMed ID: 6377830
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immortality for old drugs?
    Herxheimer A
    Lancet; 1984 Jun; 1(8392):1460-1. PubMed ID: 6145891
    [No Abstract]   [Full Text] [Related]  

  • 34. Monitoring medicines: opportunity knocks.
    Snell E
    Br Med J (Clin Res Ed); 1987 Nov; 295(6607):1209. PubMed ID: 3120947
    [No Abstract]   [Full Text] [Related]  

  • 35. Why do doctors not report adverse drug reactions?
    Leiper JM; Lawson DH
    Neth J Med; 1985; 28(12):546-50. PubMed ID: 3911083
    [No Abstract]   [Full Text] [Related]  

  • 36. Statewide test of a new postmarketing drug surveillance system.
    Fisher S; Bryant SG; Solovitz BL; Kluge RM
    Tex Med; 1987 Aug; 83(8):59-62. PubMed ID: 3660262
    [No Abstract]   [Full Text] [Related]  

  • 37. Postmarketing follow-up: physicians have key role.
    Goldsmith MF
    JAMA; 1985 Oct; 254(16):2217. PubMed ID: 4046146
    [No Abstract]   [Full Text] [Related]  

  • 38. The yellow card: mark II.
    Lawson DH
    BMJ; 1990 Dec; 301(6763):1234. PubMed ID: 2271823
    [No Abstract]   [Full Text] [Related]  

  • 39. [Drug by drug imputation of adverse effects in drug monitoring. Attempted comparison of different methods].
    Lagier G; Vincens M; Lefebure B; Frelon JH
    Therapie; 1983; 38(3):295-302. PubMed ID: 6612666
    [No Abstract]   [Full Text] [Related]  

  • 40. Postmarketing surveillance methodologies.
    Edlavitch SA
    Drug Intell Clin Pharm; 1988 Jan; 22(1):68-78. PubMed ID: 3280280
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.